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a b s t r a c t
Introduction: The influenza vaccine is less immunogenic in older than younger adults, and the duration of
protection is unclear. Determining if protection persists beyond a typical seasonal epidemic is important
for climates where influenza virus activity is year-round.
Methods: A systematic review protocol was developed and registered with PROSPERO
[CRD42015023847]. Electronic databases were searched systematically for studies reporting
haemagglutination-inhibition (HI) titres 180–360 days following vaccination with inactivated trivalent
seasonal influenza vaccine, in adults aged P65 years. Geometric mean titre (GMT) and seroprotection
(HI titre P1:40) at each time point was extracted. A Bayesian model was developed of titre trajectories
from pre-vaccination to Day 360. In the meta-analysis, studies were aggregated using a random-effects
model to compare pre-vaccination with post-vaccination HI titres at Day 21–42 (‘seroconversion’), Day
180 and Day 360. Potential sources of bias were systematically assessed, and heterogeneity explored.
Results: 2864 articles were identified in the literature search, of which nineteen met study inclusion/
exclusion criteria. Sixteen studies contained analysable data from 2565 subjects. In the Bayesian model,
the proportion of subjects seroprotected increased from 41–51% pre-vaccination to 75–78% at serocon-
version. Seroprotection subsequently fell below 60% for all serotypes by Day 360: A/H1 42% (95% CI
38–46), A/H3 59% (54–63), B 47% (42–52). The Bayesian model of GMT trajectories revealed a similar pat-
tern. By Day 360, titres were similar to pre-vaccination levels. In the meta-analysis, no significant differ-
ence in proportion of subjects seroprotected, 0 (0.11, 0.11) or in log2GMT 0.30 (0.02, 0.63) was
identified by Day 360 compared with pre-vaccination. The quality of this evidence was limited to mod-
erate on account of significant participant dropout.
Conclusions: The review found consistent evidence that HI antibody responses following influenza vacci-
nation do not reliably persist year-round in older adults. Alternative vaccination strategies could provide
clinical benefits in regions where year-round protection is important.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
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1. Introduction
Influenza is a common viral respiratory infection, which world-
wide causes substantial morbidity and mortality, particularly at
extremes of age [1,2]. Influenza vaccination is the primary tool
available for disease control but immune responses to vaccination
are reduced in the elderly compared with younger, healthy adults
[3]. Persistence of vaccine-induced immunity over periods longer
than a typical winter season have not been widely investigated,
but similar to short term responses a reduced duration of persis-
tence and hence protection against infection may be expected [4].
The primary immune response to the standard inactivated
influenza vaccine is strain-specific antibody to surface haemagglu-
tinin (HA) [5]. These antibodies mediate protection against infec-
tion by interfering with virus binding to host-cell receptors, and
are measured with standardised Haemagglutination-Inhibition
(HI) Assays [6]. Currently, age specific immunogenicity criteria
based on the HI titre are used by the regulatory committees of
the European Medicines Agency (EMA) and Federal Drug adminis-
tration (FDA) [7]. For example, a HI titre ofP1:40 is conventionally
considered ‘seroprotection’, and more than 70% of younger adults,
or 60% of older adults must reach this threshold for licensing.
A literature review published in 2008 studied antibody persis-
tence in the elderly (>60 years) [8]. Up to 16 weeks post-
vaccination the authors did not find evidence for substantial wan-
ing of seroprotection. This reviewwas primarily qualitative and did
not attempt to apply statistical methods to reported outcomes.
Beyond this review, antibody persistence in the elderly has not
been systematically assessed and a number of new studies provid-
ing data on antibody persistence have since been published.
Waning of vaccine effectiveness over the course of a winter sea-
son has been reported from a number of surveillance studies in
Europe and Australia [9–11]. For example, in a study in Spain, vac-
cine effectiveness declined from 61% in the first 100 days after vac-
cination to 42% between days 100–119, and no protection after
120 days. This decline in effectiveness was most significant in the
elderly aged over 65 years. These studies used the test-negative
case-control design, and so do not include accompanying serolog-
ical data. It is not clear to what extent this decline in effectiveness
reflects loss of vaccine-induced immune responses, or reduced
vaccine-strain matching from antigenic drift in circulating strains.
Limited data is available from studies of antibody persistence
after influenza infection. An observational study monitored titre
trajectories in subjects who were assessed to be infected with A/
H1N1 during the 2009 pandemic (seroconversion without vaccina-
tion) [12]. In 71% haemagglutination-inhibition (HI) antibody titres
wereP1:40 immediately after the epidemic peak. This declined to
25% of subjects at 6 months, and only 14% at 1 year after the
pandemic. In a sub-group analysis of the small number of elderly
subjects in the cohort, the rate of antibody decline was signifi-
cantly faster.
The duration of protection following vaccination is of particular
public health importance in countries which report more than a
single annual influenza season. Biannual epidemics, triannual
epidemics and year round virus activity are described in tropical
countries, from Indonesia and Malaysia to Peru and Mexico
[13,14]. Despite the difference in seasonality, the burden of disease
from influenza in countries with tropical, sub-tropical and temper-
ate climates has been reported to be similar [15]. The implication
of this differing epidemiology for vaccination schedules is yet to
be understood. For example, recommendations for influenza vac-
cine timing from the World Health Organization (WHO) are based
the pattern of influenza virus activity rather than prospective stud-
ies of year-round vaccine effectiveness [16,17].
With year-round influenza virus activity in the tropics, year-
round seroprotection is expected to be beneficial, but is least likely
to be attained in populations such as the elderly with impaired
immune responses. This study is a systematic review and meta-
analysis of the available evidence for year-round persistence of
vaccine-induced antibody following trivalent, inactivated, seasonal
influenza vaccination in the elderly.
2. Materials and methods
An abbreviated study protocol is available from the National
Institute for Health Research International Prospective Register of
Systemic Reviews (PROSPERO), registration number
CRD42015023847 [18]. The Preferred Reporting Items for System-
atic Reviews andmeta-Analyses (PRISMA) checklist for reporting of
systematic review was also followed [19].
2.1. Search strategy and study selection
A search strategy was developed using the PICOST framework.
Study inclusion and exclusion criteria are presented in Table 1.
Population: Elderly P65 years
Intervention: Trivalent inactivated seasonal influenza vaccina-
tion administered by intra-muscular injection
Comparison: No comparative group (e.g. healthy younger
adults) will be included. HI antibody responses at selected time
points will be compared with the pre-vaccination results.
Outcome: HI geometric mean titre (GMT) from 180 to 360 days
after vaccination and proportion with GMTsP 1:40 per Centre
for Biologics Evaluation and Research (CBER) criteria [20]
Situation: For immunologic studies, the country in which the
study is performed is not important
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Type of Study: Any study type - observational or randomised
controlled trial (RCT).
A publication date limit of 1977 was chosen to reflect the year
when a third co-circulating seasonal influenza strain (H1N1) was
recognised and WHO recommendations switched from a bivalent
to trivalent influenza vaccine [21]. The search construct developed
for MEDLINE is available in the Supplementary Material. This was
subsequently adapted for other information sources as required.
Results were limited to human subjects and English language
records.
Information sources searched to identify relevant literature
included the MEDLINE, EMBASE and Global Health databases, the
Cochrane Database of Systematic Reviews, Clinicaltrials.gov and
reference lists of all included studies. After removal of duplicates,
a three-stage screening process was used: reviewing title, then
abstract and finally full text where possible.
2.2. Data collection
Data was extracted by a single reviewer using a template
adapted from Cochrane.org. Data was collected as presented, with
estimates of numerical values made where only graphical data was
supplied. Verification of entered data was performed by an inde-
pendent recollection of data from the source manuscript. Corre-
sponding authors were contacted to request for further data or
clarifications where necessary. Data that was not published in peer
reviewed literature, but available in clinicaltrials.gov study results
or study sponsor trial registries were included. Further systematic
search for grey or unpublished literature was not performed. Sero-
protection and GMT outcome data were collected for each influ-
enza strain subjects were vaccinated with. Retention rates were
calculated using the GMT data presented for A/H1.
2.3. Risk of bias and quality of evidence assessment
Risk of bias was assessed using the Cochrane Collaboration’s
tools for assessing RCTs and non-randomised studies [22]. Each
study was assessed as at either low, high or unclear risk for bias.
The terminology for assessing risk of bias was harmonised for
cohort and RCTs, however, bias assessments are not equivalent
between scales. Studies were not excluded from the systematic
review or meta-analysis as a result of this assessment.
The GRADE approach was used to evaluate the overall quality of
evidence for each outcome [23]. Because the study compared pre-
and post-vaccination results in the same subjects, both RCTs and
observational studies started as ‘high quality’. They were down-
graded by one level for serious (or by two for very serious) study
limitations identified in the risk of bias assessment such as issues
that may limit the generalisability of the reported results, inconsis-
tency of results between studies, or potential publication bias.
2.4. Synthesis of results
Seroprotection and GMT were analysed by influenza subtype A/
H1, A/H3 and type B at available time points. Number seropro-
tected (HIP 1:40) was estimated from provided data, rounded to
integers. Where GMT confidence intervals (CI) were available, the
sample standard deviation was calculated from the log2 trans-
formed values and a Student’s t distribution assumed if not stated.
Where only sub-group data was available from a study each sub-
group was entered and analysed separately.
To account for both inter- and intra-study variability, Bayesian
mixed-effect models were developed to determine an estimate of
seroprotection and GMT for each subtype. We assumed a normal
distribution for the GMT on a base-2 logarithmic scale and a bino-
mial distribution for seroprotection for each subtype. The likeli-
hood function of the GMT and seroprotection data could be then
derived using the following models:
For GMT data, we assumed a log-Normal distribution
log2ðGMTijÞ  Nðlij;r2i Þ
lij ¼ ai þ bj þ i
where GMTij is the j th observed GMT in study i, lij controls the
location of GMTij and i is the random effect term. Both ai and bj
are model parameters that need to be estimated where ai determi-
nes the study effect and bj captures the variation in time.
For seroprotection data, we assumed a binomial distribution:
xij  Binðpij;nijÞ
logitðpijÞ ¼ ai þ bj þ ei
where xij is the j th observed number of subjects with GMTsP 1:40
in study i, nij is the j th observed sample size in study i, pij gives the
estimate of seroprotection and ei is the random effect term. Again,
both ai and bj are model parameters that need to be estimated
where ai determines the study effect and bj captures the variation
in time.
Non-informative priors were adopted for model parameters.
Parameters were estimated using Markov chain Monte Carlo
Table 1
Study inclusion and exclusion criteria.
Inclusion criteria
Study performed in elderly humans (P65 years)
No restriction is placed on study population place of residence (e.g. community or long-term care facility), vaccination history or presence of chronic diseases
Studies of standard dose (15 mcg hemagglutinin per strain) trivalent inactivated seasonal influenza vaccine, without adjuvant
Studies using inactivated whole virion, split virion or subunit influenza antigen preparations
Studies reporting seroprotection and/or GMT at pre-vaccination, 21–42 days (‘seroconversion’) and at least one additional time point between 180 and 360 days
No restriction is placed on HI antibody assay methodology
Where seroprotection data is reported, only studies which use thresholds recommended by CBER will be included (P1:40)
No restriction is placed on study design – for example RCT or cohort study
Multi-year studies will be included if vaccine and/or strain composition do not change during the first year of the study
Full text of manuscript is published in English, after 1977
Exclusion criteria
Studies which include subjects due to the presence of a specific comorbidity (e.g. haemodialysis or post-solid organ transplant)
Studies using monovalent/bivalent/quadrivalent or live-attenuated seasonal influenza vaccines
Studies administering vaccine by non-parenteral or intra-dermal routes
Studies using virosomal or virus-like particle vaccines, and experimental/novel preparations
Studies using vaccines targeting non-seasonal strains, such as avian influenza
Uncontrolled trials of experimental interventions (e.g. day 28 boosters, novel adjuvants)
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with 100,000 Metropolis-Hastings iterations with a thin of 10
iterations after a burn-in period of 50,000. Point estimates are
posterior means and uncertainty intervals are 95% credible
intervals (CrI).
The proportion of subjects seroprotected and log2GMT were
compared at baseline (pre-vaccination) with Day 21–42, Day 180
and Day 360 in the meta-analysis. The Mantel-Haenszel method
was used to calculate the risk difference in seroprotection. Mean
differences in log2GMT were aggregated by inverse-variance
weighting. Random-effects models were used for all meta-
analyses to reflect the assumption that the effects being estimated
in the different studies are not identical. Sub-group analyses by
influenza subtype were also performed (A/H1, A/H3, B).
Variability of outcomes between studies was assessed using the
heterogeneity statistic I2. Possible publication bias was assessed by
visual interpretation of funnel plots.
Descriptive statistics were calculated using Microsoft Excel
2016 (Microsoft Corporation, Richmond, USA). The Bayesian bino-
mial/normal model was implemented in R version 3.2.1 (R Founda-
tion for Statistical Computing, Vienna, Austria). Meta-analyses
were calculated using RevMan v5.3 (The Cochrane Collaboration,
Copenhagen, Denmark). Statistical significance was assumed with
a 2-sided alpha of 0.05.
3. Results
3.1. Study selection and characteristics
Database searches were performed in September 2015. The
PRISMA flow diagram for the study selection process and reasons
for exclusion of studies at full-text screening are shown in Fig. 1.
Summary characteristics of the included studies are shown in
Table 2. There were fifteen randomised control trials (RCTs) and
4 cohort studies.
Fourteen of the RCTs compared standard dose inactivated triva-
lent influenza vaccine with alternative formulations (adjuvanted,
high-dose vaccine, intra-dermal vaccine or quadrivalent vaccine).
One RCT compared the effect of an oral adjuvant with placebo.
Three RCTs included an immunogenicity analysis as a subset of a
larger analysis with clinical endpoints, while the others were
designed with immunological primary endpoints. One of the
cohort studies was designed to investigate antibody persistence
in the elderly and other age groups as the primary objective. Two
cohort studies investigated serological responses to influenza vac-
cination after first and subsequent annual vaccination, while one
was an observational study of booster influenza vaccine at
12 weeks in elderly travellers.
Fig. 1. PRISMA flow diagram of study selection and reasons for study exclusion at screening of full text.
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For three studies (numbers 1, 2 and 5 in Table 2) data was not
evaluable in the Bayesian model or meta-analysis.
3.2. Risk of bias within studies
Overall nine RCTs were considered at low risk for bias, three at
high risk and for three the risk was unclear (see Supplementary
Material for full assessment). One cohort study was considered at
low risk of bias, two at high risk and for one the risk was unclear.
Six RCTs were conducted as open-label, eight observer-blinded,
and one double-blind. Although open-label studies have a greater
potential for bias when compared to blinded studies, open-label
studies were not assessed as high-risk on the basis of this because
of the immunological nature of outcomes in this review. Most of
the RCTs failed to report their allocation concealment methodol-
ogy, but as this review is not comparing outcomes between groups,
this limitation was not considered likely to cause significant bias.
For both RCT and cohort studies the major potential source of
bias was subject dropout. For three RCTs and two cohort studies,
results were selectively reported, excluding subjects who did not
have HI data for Day 180–360, or the enrolled sample size was
not clear. Two of the fourteen evaluable studies reported loss of
P10% of subjects from Day 1 vaccination to Day 180. The overall
retention rate from these thirteen studies at Day 180 was 95.1%.
Retention fell to 68.2% from Day 1 to 360 for two of the five studies
reporting this data.
In sixteen studies the number of subjects enrolled was avail-
able. 20.7% (677/3269) of subjects were excluded with no serolog-
ical data presented. It could not be evaluated if exclusion of these
subjects introduced a systematic bias in results.
3.3. Systematic review and Bayesian models of antibody persistence
The pattern of GMT and seroprotection rise and decline after
vaccination was similar across all studies. Raw data extracted is
available in the Supplementary Material. The majority of individual
studies demonstrated a good initial serological response to vacci-
nation with waning from seroconversion to Day 360. The degree
of pre-vaccination immunity and magnitude of post-vaccination
responses varied considerably. From individual studies, only one
of 11 seroprotection and three of 14 GMT comparisons demon-
strated statistically significant higher levels at Day 360 compared
with pre-vaccination.
Summary data from the Bayesian model of antibody persistence
is presented in Table 3. The estimate of population seroprotection
was just above the CBER licensure threshold of 60% at Day 180, and
by Day 360 fell below this threshold for all three serotypes.
Table 2
Summary of study characteristics.
Author,
publication
year [Ref.]
Vaccine
year
Principal
country
Study design Comparative
arm
Number
of
subjects
(IIV3
group)
Male
(%)
Average
age
(year)
Vaccine
type
Vaccine
in
previous
year (%)
Retention rate
(%, day 180/1)
Living
situation
Source
of data
1* Minutello 1999
[24]
1992 Italy RCT, observer-blind aIIV3 46 39.1 73 SU 72 NA C P
2* Van Hoecke
1996 [25]
1994 Slovakia Cohort – 495 29.5 80 SV – NA LTCF P
3 Buxton 2001
[26]
1998 Canada Cohort IIV3 booster 32 – 74 – – 96.4 (27/28) C P
4 Iorio 2007 [27] 1998 Italy Cohort – 580 10.8 81 SU/SV – NA LTCF P
5* Ben-Yehuda
2003 [28]
2000 Israel RCT, open-label Liposomal
vaccine
33 30.3 88 SV 69.7 100 (33/33) LTCF P
6 NCT00386113
[29,30]
2005 Belgium RCT, open-label aIIV3 50 62 69 SV – 100 (49/49) C R
7 NCT00377585
[31,32]
2006 US RCT, observer-blind aIIV3 737 46.8 73 SV – 91.8 (657/716) C R
8 Song 2010 [4] 2007 South
Korea
Cohort – 350 32.4 72 SV 90.1 NA C P
9 Rumke 2013
[33,34]
2007 Germany RCT, observer-blind aIIV3 200 55 73 SV – 96.3 (181/188) C P, R
10 Couch 2014
[35,36]
2008 US, RCT, observer-blind aIIV3 73 41 71.3 SV 78 100 (66/66) C P, R
11 McElhaney 2013
[37–39]
2008–10 15
countries
RCT, observer-blind aIIV3 NA 43.0 73.5 SV 72.3 100 (267/265) C P, R
12 Song 2013 [40] 2009 South
Korea
RCT, open-label aIIV3 50 51.6 73.3 SV – 75 (36/48) C P
13 Tinoco 2014
[41,42]
2010 Canada RCT, double-blind IIV4 NA NA NA SV – 100 (38/38) C P
14 Frey 2014 [43] 2010 US RCT, observer-blind aIIV3 NA 34 72 SU – NA C P, A
15 Scheifele 2013
[44]
2011 Canada RCT, observer-blind aIIV3,
intradermal
IIV3
307 40.7 74 SU 94.5 99 (301/304) C P, R
16 Saiki 2013 [45] 2011 Japan RCT, open-label Oral adjuvant 46 29.4 86 – – 97.8 (44/45) LTCF P
17 Seo 2014 [46] 2011 South
Korea
RCT, open-label aIIV3,
intradermal
IIV3
118 38.9 73 SU – 100 (113/113) C P
18 Nace 2015 [47] 2011–12 US RCT, observer-blind High dose IIV3 102 32 87 – – 84.7 (83/98) LTCF P
19 Chan 2014 [48] 2013 Hong
Kong
RCT, open-label Intra-dermal
IIV3
50 44 84 SV 90 96 (48/50) LTCF P, A
* Not included in quantitative analysis. N/A, not available, Randomised Control Trial, RCT; Subunit, SU; Split-Virion, SV; Community, C; Long-term Care Facility, LTCF;
Publication, P; Author, A; Clinical Trial Registry, R.
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3.4. GMT meta-analysis
Fifteen studies reported the pre-vaccination GMT and were
included in the meta-analysis. All fifteen provided data for compar-
ison at Day 21–42, fourteen for comparison at Day 180, and four for
Day 360.
In the overall analysis, combining estimates for influenza A/H1,
A/H3 and B, log2GMT difference declined linearly from Day 21–42
to Day 360, implying an exponential decay in GMT titres (Fig. 2).
GMTs at Day 360 were not significantly different from pre-
vaccination (0.30, 95% CI 0.02, 0.63). This result was consistent
when analysed by subtype A/H3 (0.47, 95% CI0.17, 1.15) and type
B (0.27, 95% CI 0.51, 0.04). While a significant difference at
Day 360 was detected for A/H1 (0.57, 95% CI 0.23, 0.91), the overall
trend was similar.
3.5. Seroprotection meta-analysis
Thirteen studies which reported the proportion of subjects who
were seroprotected pre-vaccination were included in the meta-
analysis. All provided data for comparison at Day 21–42, twelve
for comparison at Day 180, and three for Day 360.
Similar to the analysis of GMTs, when combining influenza A/
H1, A/H3 and B, seroprotection risk difference compared with
pre-vaccination declined linearly from Day 21–42 to Day 360
(Fig. 2), and no significant difference in seroprotection compared
with pre-vaccination was detected by Day 360 (0, 95% CI 0.11,
0.11). Analysis by individual influenza subtypes A/H1, A/H3, and
type B were consistent, with no significant difference from the
pre-vaccination level for each at Day 360: A/H1 (0.09, 95% CI
0.15, 0.33), A/H3 (0.08, 95% CI 0.11, 0.12), B (0, 95% CI
0.13, 0.13).
3.6. Risk of bias between studies
Substantial heterogeneity between studies was evident in the
main pooled analysis from the heterogeneity statistic I2 (89–
98%). This estimate of heterogeneity was generally lower for the
Day 360 and individual subtype analyses.
No asymmetry was evident from examination of the funnel
plots for seroprotection risk difference at all time points. For
GMT mean difference, asymmetry was evident in the Day 21–42
funnel plots (Fig. 3). Asymmetry was primarily a result of a larger
than expected mean difference (MD) from four data points, all pro-
vided by A/H1 and A/H3 from study 13 (Tinoco et al.). Funnel plots
were similar for Day 180, while no asymmetry was apparent at Day
360 (see Supplementary Material).
3.7. Quality of evidence
Estimates of differences between GMT and seroprotection pre-
vaccination and Day 360 were assessed to be of moderate-
Table 3
Estimates of population GMT and seroprotection (HIP 1:40) at each time point by subtype.
Pre-vaccination Day 21–42 Day 180 Day 360
GMT (95% Credible Intervals)
A/H1 20.3 (18.8–22.0) n = 2537 65.8 (60.5–71.0) n = 2536 33.6 (31.1–36.5) n = 2327 22.6 (19.8–26.4) n = 734
A/H3 23.6 (21.7–25.6) n = 2538 83.3 (76.1–90.5) n = 2537 45.3 (41.6–49.5) n = 2327 36.0 (30.9–41.4) n = 734
B 32.0 (29.2–35.3) n = 2470 78.2 (71.5–86.2) n = 2469 54.9 (49.9–60.1) n = 2327 28.2 (23.1–34.1) n = 666
Seroprotection rate (95% Credible Intervals)
A/H1 0.41 (0.39–0.44) n = 2155 0.78 (0.76–0.80) n = 2157 0.61 (0.59–0.64) n = 1950 0.42 (0.38–0.46) n = 481
A/H3 0.45 (0.43–0.47) n = 2155 0.78 (0.76–0.79) n = 2157 0.62 (0.60–0.64) n = 2003 0.59 (0.54–0.63) n = 481
B 0.51 (0.50–0.53) n = 2088 0.75 (0.73–0.77) n = 2090 0.66 (0.64–0.68) n = 1950 0.47 (0.42–0.52) n = 481
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forest plots for Day 360 (B + D).
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quality. Despite heterogeneity in vaccine responses initially, study
results were consistent by Day 360. This assessment was consid-
ered as only moderate-quality evidence because of problems with
incomplete reporting of outcome data following subject dropout.
The quality of evidence for the effect size estimates of the change
in GMT and seroprotection compared between pre-vaccination at
Day 21–42 and Day 180 were assessed as low due to heterogeneity.
4. Discussion
This meta-analysis finds robust evidence to support the conclu-
sion that in the elderly older than 65 years, haemagglutination-
inhibition (HI) antibody responses following influenza vaccination
does not reliably persist year-round. The findings were consistent
between the Bayesian model and the meta-analysis, and consistent
when using seroprotection (HIP 1:40) or GMT as the endpoint.
Overall, an exponential decay in antibody titres was evident from
Day 21–42 to Day 360 after vaccination, as reflected in a linear
decline in the estimates of mean difference in log2GMT. By Day
360, GMTs and the proportion of subjects seroprotected were not
significantly different from pre-vaccination levels, and for seropro-
tection, below the CBER licensing threshold.
There is a lack of clinical studies on vaccine efficacy or effective-
ness from elderly populations in tropical countries to confirm the
clinical significance of this finding. However, the immunological
evidence presented here suggests that the elderly in countries with
biannual and year-round influenza epidemics would benefit from
an alternative to the currently recommended annual standard dose
trivalent inactivated influenza virus (IIV3). Newer vaccine formula-
tions which include an immunological adjuvant - MF59 or AS03 -
or a higher antigen dose are more immunogenic than standard
IIV3 [49,50]. Over a winter season these have been reported to
reduce infection rates compared with IIV3 in double-blind RCTs,
but it is not clear if this would translate into longer term benefits
[37,51]. For IIV3 with adjuvant, serological outcome data is mixed
at Day 180, with reports of significantly higher HI titres compared
to standard IIV3 in some studies [40,44,46]. Any serological benefit,
however, does not appear to persist to Day 360 [24,37,43]. Anti-
body persistence data beyond Day 180 is not currently available
for the high dose vaccine. An alternative approach to changing
the formulation may be to vaccinate more regularly – for example
before each season in countries with biannual epidemics. The out-
comes of such a strategy has not been investigated.
Despite the established use of a HI titre ofP1:40 to define sero-
protection, this threshold is associated with only 40–70% protec-
tion from infection in the elderly and younger adults [52,53].
Using this threshold will underestimate the changes in proportion
of subjects who become susceptible to infection when GMTs
decline. Coudeville et al. developed a protection curve to model
the probability of protection at different HI titres [54]. As the HI
titre increases from 1:40 to 1:100, the probability of protection
increases to approximately 90%, with marginal benefits beyond
this. Thus, even if vaccine responses meet the ‘seroprotection’
cut-off of 1:40 at Day 180, decay in titres in the elderly may result
in a substantial proportion of the population becoming susceptible
to infection, including before the end of a seasonal epidemic in
temperate countries. Clearly, if following seroconversion signifi-
cant susceptibility to infection develops by Day 180, this is only
likely to increase further by Day 360 and offer inadequate efficacy
with an annual vaccination strategy for elderly individuals in the
tropics.
The persistence of other immune responses to vaccination also
needs to be considered. Microneutralization (MN) assays may be a
more accurate measure of humoral immunity than the HI assay,
and MN titres also correlate with protection against influenza
infection [55,56]. Cell-mediated immunity reduces the severity of
disease after infection, and while this is only weakly induced by
IIV3 it may still have a clinically significant role [57]. Vaccine-
induced T-cell responses have been reported to be better correlates
of protection than HI titres in the elderly [58]. This review did not
seek to identify studies which explored persistence of these
immune responses in the elderly after influenza vaccination, but
this would be useful to investigate.
There was substantial variability in baseline GMTs, seroprotec-
tion levels, and the magnitude of vaccination responses between
studies. Some of this variability is influenza strain dependent,
and reflects the immunogenicity of individual strains, and host
immunological memory from previous infection or vaccination
exposure. The influence of pre-existing immunity on vaccine
responses is complex. An observational study of mainly younger
adults and children suggested interference in vaccine responses
Fig. 3. Funnel plots at Day 21–42 versus pre-vaccination for (A) mean difference (MD) in log2GMT and (B) risk difference (RD) in seroprotection. Ringed outliers are from
study 13 (Tinoco et al.). Grey-filled circles represent subtype A/H1, Black A/H3, White B. Dashed line is the effect estimate.
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from previous vaccination [59]. However, a meta-analysis identi-
fied high pre-vaccination titres and previous vaccination as predic-
tors of higher vaccine responses [60]. Influenza vaccination rates in
the year prior to study enrolment were high in those studies that
reported this (70–100%), while information on recent influenza
infections were not available.
Influenza independent mechanisms which will affect vaccine
response in the elderly include participant health, concomitant
medications, and in particular the impact of immunosenescence.
RCTs generally excluded participants with unstable health condi-
tions or immunosuppression due to the presence of specific co-
morbidities or treatment with cytotoxic chemotherapy or high-
dose corticosteroids. Most studies also recruited volunteers from
the community rather than long-term care facilities. It is not clear
if the prevalence and severity of common chronic diseases such as
diabetes mellitus and chronic obstructive pulmonary disease in
recruited subjects is similar to the general population. While these
conditions are associated with increased morbidity and mortality
after influenza infection, their impact on vaccine responses is less
certain [61–63]. In a study of antibody persistence after vaccina-
tion among subjectsP50 years neither age nor presence of chronic
disease were significantly associated with maintenance of seropro-
tection at 8 months [64]. Song et al. also did not find the presence
of chronic diseases as a significant risk factor for reduced antibody
persistence at 12 months [4].
Immunosenescence describes the complex process of immune
dysregulation that develops with aging, but defining immunose-
nescence by a single variable – age – as is traditional in vaccina-
tion guidelines, is an over-simplification [65]. The pace of
immunosenescence development is the result of numerous inter-
actions between host genetic and environmental processes which
also includes biological sex, nutritional status, chronic stress,
chronic infection, and other co-morbidities. An important sys-
temic cause and consequence of immunosenescence may be the
chronic release of inflammatory cytokines such as TNF, IL-1 and
IL-6 [66]. This syndrome of ‘inflammaging’ correlates with pro-
gression of a number of chronic diseases and contributes to func-
tional decline and frailty in the elderly. In vitro studies have also
implicated inflammaging as associated with reduced influenza
vaccine response [67].
It is debatable what age cut-off is most appropriate for this
review – the older adult immunogenicity criteria used by the
FDA apply when age is P65 years, while for the EMA the cut-off
is >60 years. A number of studies were excluded from this review
because they enrolled younger subjects. Lowering the inclusion
criteria to >60 years would probably not have significantly altered
its findings, although we can expect that vaccine responses would
have been better and more durable with the addition of younger
individuals. Deeper understanding of the impact of age and other
risk factors for immunosenescence was beyond the scope of this
review, but could be further explored if patient level data were
available.
The findings of this meta-analysis were consistent when anal-
ysed by GMT or seroprotection, and in both the overall analysis
or by influenza subtypes. The variability between subjects and
studies places limits on applying the estimates of the magnitude
of changes in GMT and seroprotection to individual patients or
influenza strains. Some of this variability is mitigated by the
matched design of the meta-analysis, with control and experimen-
tal outcomes measured in the same population. There was a signif-
icant loss of participants by Day 360 in all the studies included in
the meta-analysis. Reasons for dropout were generally not avail-
able, but participant morbidity and mortality is likely to be an
important contributor. This is likely to bias study results towards
more sustained immune responses than the general elderly
population.
Identification of studies in this review may have missed rele-
vant studies, through human error, imperfections in the literature
databases or search methodology, or a failure to identify unpub-
lished studies. As relatively few studies included evaluable data
at Day 360, this could impact findings of the statistical analysis.
However, more than 2000 individual comparisons were available
for analysis at Day 360, and so new data is less likely to impact
the overall trend of antibody decline after seroconversion.
In conclusion, the decline from Day 21–42 to 360, in GMTs and
the proportion of subjects seroprotected suggests that clinical pro-
tection is not likely to persist year-round in the elderly. Confirma-
tion of this finding with studies of vaccine effectiveness is
necessary, but identifying alternative vaccination schedules which
provide year-round protection against influenza infection is likely
to offer substantial public health benefit, particularly in tropical
countries with year-round virus activity.
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